{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:03:12Z","timestamp":1760061792501,"version":"3.37.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602950"],"award-info":[{"award-number":["81602950"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chengdu Science and Technology Bureau International Cooperation","award":["2019-GH02-00036-HZ"],"award-info":[{"award-number":["2019-GH02-00036-HZ"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A simple and accurate chiral liquid chromatographic method was developed for enantiomeric resolution and determination of 2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-(1,3-thiazol-2-yl)acetamide (EAI045). The enantiomers of EAI045 were baseline resolved on a Chiralpak AD-H (250\u00a0mm\u00a0\u00d7\u00a04.6\u00a0mm, 5\u00a0\u03bcm) column using a mobile phase system containing n-hexane: 2-propanol (75: 25\u00a0v\/v) at a flow rate of 1\u00a0mL\u00a0min\u22121 at 30\u00b0C. The eluted analytes were subsequently detected with an ultraviolet detector at 254\u00a0nm. The effects of organic modifiers and temperature on the enantioselectivity and resolution of the enantiomers were evaluated. The calibration curves were plotted within the concentration range between 2 and 600\u00a0\u03bcg\u00a0mL\u22121 (n\u00a0=\u00a011), and recoveries between 98.74% and 101.52% were obtained, with relative standard deviation\u00a0&amp;lt;\u00a01.4%. The limit of detection and limit of quantitation for R-enantiomer were 0.94 and 3.07\u00a0\u03bcg\u00a0mL\u22121 and for S-enantiomer were 0.86 and 2.84\u00a0\u03bcg\u00a0mL\u22121, respectively. The validated method was found to be suitable for enantiomeric separation and sufficiently accurate for the determination of enantiomeric purity of EAI045 in bulk drugs.<\/jats:p>","DOI":"10.1093\/chromsci\/bmz125","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T12:07:42Z","timestamp":1577102862000},"page":"562-568","source":"Crossref","is-referenced-by-count":1,"title":["A Validated LC Method for the Enantiomeric Separation of EAI045 on Chiral Stationary Phase"],"prefix":"10.1093","volume":"58","author":[{"given":"Xiuli","family":"Wu","sequence":"first","affiliation":[{"name":"Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yange","family":"Zhang","sequence":"first","affiliation":[{"name":"Cosmetic Plastic and Burn Surgery, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhen","family":"Li","sequence":"first","affiliation":[{"name":"Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingmei","family":"Liu","sequence":"first","affiliation":[{"name":"Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Yang","sequence":"first","affiliation":[{"name":"Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijie","family":"Wang","sequence":"first","affiliation":[{"name":"Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwen","family":"Zhang","sequence":"first","affiliation":[{"name":"Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,18]]},"reference":[{"key":"2020060505400513800_ref1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11684-016-0488-1","article-title":"Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors","volume":"10","author":"Wang","year":"2016","journal-title":"Frontiers of Medicine"},{"key":"2020060505400513800_ref2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncology"},{"key":"2020060505400513800_ref3","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: Analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu","year":"2015","journal-title":"Annals of Oncology"},{"key":"2020060505400513800_ref4","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nature Reviews Cancer"},{"key":"2020060505400513800_ref5","doi-asserted-by":"crossref","first-page":"E3595","DOI":"10.1073\/pnas.1220050110","article-title":"Mechanism for activation of mutated epidermal growth factor receptors in lung cancer","volume":"110","author":"Red Brewer","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"2020060505400513800_ref6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nature Reviews Cancer"},{"key":"2020060505400513800_ref7","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1021\/acs.jmedchem.5b01082","article-title":"Targeting drug resistance in EGFR with covalent inhibitors: A structure-based design approach","volume":"58","author":"Engel","year":"2015","journal-title":"Journal of Medicinal Chemistry"},{"key":"2020060505400513800_ref8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40164-016-0052-3","article-title":"Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer","volume":"5","author":"Berz","year":"2016","journal-title":"Experimental Hematology & Oncology"},{"key":"2020060505400513800_ref9","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaoncol.2015.1066","article-title":"Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: Emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain","volume":"1","author":"Yu","year":"2015","journal-title":"JAMA Oncology"},{"key":"2020060505400513800_ref10","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.jtho.2015.12.093","article-title":"Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung cancer","volume":"11","author":"Song","year":"2016","journal-title":"Journal of Thoracic Oncology"},{"key":"2020060505400513800_ref11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2016.11.008","article-title":"EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance","volume":"385","author":"Wang","year":"2017","journal-title":"Cancer Letters"},{"key":"2020060505400513800_ref12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"2020060505400513800_ref13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-016-0290-1","article-title":"EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer","volume":"9","author":"Wang","year":"2016","journal-title":"Journal of Hematology & Oncology"},{"key":"2020060505400513800_ref14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/chir.530040513","article-title":"FDA\u2019s policy statement for the development of new stereoisomeric drugs","volume":"4","year":"1992","journal-title":"Chirality"},{"key":"2020060505400513800_ref15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/chromsci\/bmx098","article-title":"Enantioseparation of substituted 1, 3-Diazaspiro [4.5] Decan-4-ones: HPLC comparative study on different polysaccharide type chiral stationary phases","volume":"56","author":"Aboul-Enein","year":"2018","journal-title":"Journal of Chromatographic Science"},{"key":"2020060505400513800_ref16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/chromsci\/bmx061","article-title":"Liquid chromatographic chiral separation of Acenocoumarol and its Hemiketal form","volume":"55","author":"Kraimi","year":"2017","journal-title":"Journal of Chromatographic Science"},{"key":"2020060505400513800_ref17","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/chromsci\/bmx023","article-title":"Determination of Bortezomib in API samples using HPLC: assessment of enantiomeric and diastereomeric impurities","volume":"55","author":"Kamalzadeh","year":"2017","journal-title":"Journal of Chromatographic Science"},{"key":"2020060505400513800_ref18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-4347(00)00267-X","article-title":"Chiral separation by simultaneous use of vancomycin as stationary phase chiral selector and chiral mobile phase additive","volume":"745","author":"Sun","year":"2000","journal-title":"Journal of Chromatography B"},{"key":"2020060505400513800_ref19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.talanta.2003.10.032","article-title":"Chiral separation of enantiomers of amino acid derivatives by high-performance liquid chromatography on a norvancomycin-bonded chiral stationary phase","volume":"62","author":"Ding","year":"2004","journal-title":"Talanta"},{"key":"2020060505400513800_ref20","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s10337-017-3338-7","article-title":"Determination of enantiomeric purity of GSK962040 based on liquid chromatography using chiral stationary phase combined with a pre-column derivatization procedure","volume":"80","author":"Ye","year":"2017","journal-title":"Chromatographia"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/chromsci\/article-pdf\/58\/6\/562\/33346272\/bmz125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/chromsci\/article-pdf\/58\/6\/562\/33346272\/bmz125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T08:14:56Z","timestamp":1591431296000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/58\/6\/562\/5821452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,18]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,4,18]]},"published-print":{"date-parts":[[2020,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmz125","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"type":"print","value":"0021-9665"},{"type":"electronic","value":"1945-239X"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,4,18]]}}}